# Broad Institute of MIT and Harvard

Source: https://onco.cc/institutions/broad-institute/  
OnCo record `broad-institute` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Broad Institute is the genomics powerhouse behind DepMap, cBioPortal co-development, and the Cancer Cell Line Encyclopedia.

## Summary

The Broad Institute of MIT and Harvard in Cambridge, Massachusetts, is the genomics research institute behind DepMap, the Cancer Cell Line Encyclopedia, PRISM drug screening and the co-development of cBioPortal; its Cancer Program under Getz and Matthew Meyerson, with Zhang's CRISPR technology, makes it the reference source for functional genomics in cancer. OnCo links it to CRISPR functional genomics and synthetic lethality, to the Cancer Dependency Map and TCGA Pan-Cancer Atlas papers, and to people including Todd R. Golub and Francisca Vazquez. It bears on bottlenecks about preclinical models that do not predict people and undruggable drivers, and on the idea of an open foundation model of the cancer cell trained on perturbation data. Whether cell-line dependencies translate to patients is the open question. The Koch Institute and Wellcome Sanger Institute are its linked partners.

## Fields

- Kind: Institution
- Last checked: 2026-09-04
- City: Cambridge, MA, US
- Type: research-institute
- Website: https://www.broadinstitute.org

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Broad_Institute
- Official website: https://www.broadinstitute.org

## Connected records

- technologies: [Boltz-1 / Boltz-2 (MIT, open)](https://onco.cc/technologies/boltz/), [CRISPR functional genomics](https://onco.cc/technologies/crispr-screens/), [Synthetic lethality approaches](https://onco.cc/technologies/synthetic-lethality-approaches/)
- people: [Andrew J. Aguirre](https://onco.cc/people/andrew-aguirre/), [Bradley E. Bernstein](https://onco.cc/people/bradley-bernstein/), [Catherine J. Wu](https://onco.cc/people/catherine-wu/), [Eli Broad](https://onco.cc/people/eli-broad/), [Faisal Mahmood](https://onco.cc/people/faisal-mahmood/), [Feng Zhang](https://onco.cc/people/feng-zhang/), [Francisca Vazquez](https://onco.cc/people/francisca-vazquez/), [Gad Getz](https://onco.cc/people/gad-getz/), [Matthew Meyerson](https://onco.cc/people/matthew-meyerson/), [Todd R. Golub](https://onco.cc/people/todd-golub/), [Viktor A. Adalsteinsson](https://onco.cc/people/viktor-adalsteinsson/)
- key papers: [Comprehensive genomic characterization of squamous cell lung cancers](https://onco.cc/key-papers/paper-tcga-lung-squamous-nature-2012/), [Comprehensive molecular characterization of human colon and rectal cancer](https://onco.cc/key-papers/paper-tcga-colorectal-comprehensive-characterization-nature-2012/), [Comprehensive molecular profiling of lung adenocarcinoma](https://onco.cc/key-papers/paper-tcga-lung-adenocarcinoma-nature-2014/), [Defining a Cancer Dependency Map: which genes each cancer cell line cannot live without](https://onco.cc/key-papers/paper-depmap-tsherniak-cell-2017/), [Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas](https://onco.cc/key-papers/paper-campbell-pan-lung-somatic-alterations-nat-genet-2016/), [EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy](https://onco.cc/key-papers/paper-paez-egfr-mutations-gefitinib-science-2004/), [Genomic correlates of immune-cell infiltrates in colorectal carcinoma](https://onco.cc/key-papers/paper-giannakis-genomic-correlates-immune-colorectal-cell-rep-2016/), [Integrated genomic characterization of pancreatic ductal adenocarcinoma](https://onco.cc/key-papers/paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017/), [Jaiswal: clonal haematopoiesis, the pre-leukaemic clones in most people over 70](https://onco.cc/key-papers/paper-jaiswal-chip-nejm-2014/), [Punctuated evolution of prostate cancer genomes](https://onco.cc/key-papers/paper-baca-punctuated-evolution-chromoplexy-cell-2013/), [Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine](https://onco.cc/key-papers/paper-aguirre-real-time-genomic-characterisation-pancreatic-cancer-discov-2018/), [TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features](https://onco.cc/key-papers/paper-tcga-pancancer-atlas-cell-2018/)
- collections: [DepMap (Cancer Dependency Map)](https://onco.cc/collections/depmap/)
- bottlenecks: [Data silos](https://onco.cc/bottlenecks/b-data-silos/), [Lab models that fail to predict what happens in patients](https://onco.cc/bottlenecks/b-preclinical-models/), [Preclinical results do not reproduce](https://onco.cc/bottlenecks/b-reproducibility/), [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/), [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/), [Too many combinations to test](https://onco.cc/bottlenecks/b-combination-space/)
- ideas: [A precompetitive consortium for the twenty hardest cancer targets](https://onco.cc/ideas/idea-bio1-undruggable-open-consortium/), [An open atlas of collateral sensitivity for every approved targeted drug](https://onco.cc/ideas/idea-bio1-collateral-sensitivity-atlas/), [An open foundation model of the cancer cell trained on perturbation data](https://onco.cc/ideas/idea-data-open-cell-foundation-model/), [An open map of which cancer proteins any drug can stick to](https://onco.cc/ideas/idea-bio1-covalent-ligandability-atlas/), [An open model of every cancer cell state, built from perturbation atlases](https://onco.cc/ideas/idea-moon-open-cancer-cell-state-model/), [An open-science consortium on the undruggable drivers, open until a candidate](https://onco.cc/ideas/idea-fund-precompetitive-undruggable-consortium/), [Attack the backup copy when a tumour has lost the original gene](https://onco.cc/ideas/idea-bio1-paralog-synthetic-lethality/), [Break up the liquid droplets where oncogenic transcription happens](https://onco.cc/ideas/idea-bio1-condensate-disruptors/), [Kill drug-tolerant persisters through ferroptosis](https://onco.cc/ideas/idea-ferroptosis-persisters/), [Let patients themselves donate their records and samples for ultra-rare cancers](https://onco.cc/ideas/idea-bio2-patient-partnered-rare-commons/), [Pick the laboratory model that matches the patient, not the one to hand](https://onco.cc/ideas/idea-bio1-model-patient-matching/), [Pool every multi-sample tumour genome into one open evolution atlas](https://onco.cc/ideas/idea-bio1-federated-evolution-atlas/), [Score every model system on how well it predicted real trial results](https://onco.cc/ideas/idea-bio1-model-predictivity-benchmark/)
- pathways: [Clonal evolution & minimal residual disease](https://onco.cc/pathways/clonal-evolution/), [Clonal haematopoiesis (CHIP)](https://onco.cc/pathways/clonal-haematopoiesis/), [Ferroptosis & regulated cell death](https://onco.cc/pathways/ferroptosis-cell-death/), [SWI/SNF chromatin remodelling](https://onco.cc/pathways/swi-snf-chromatin/)
- institutions: [David H. Koch Institute for Integrative Cancer Research at MIT](https://onco.cc/institutions/mit-koch/), [Howard Hughes Medical Institute](https://onco.cc/institutions/hhmi/), [Wellcome Sanger Institute](https://onco.cc/institutions/wellcome-sanger/)

---
JSON: https://onco.cc/api/v1/entities/broad-institute.json